Helix BioPharma Corp., a clinical-stage oncology company focused on developing therapies for difficult-to-treat cancers, announced today that Janusz Grabski has resigned from its Board of Directors with immediate effect. Concurrently, the Board has formally appointed Thomas Mehrling, M.D., Ph.D., the company's Chief Executive Officer, as a director, pursuant to the Board nomination right granted to Laevoroc Immunology AG in connection with Helix's 2025 acquisition of substantially all of the assets of Laevoroc Immunology AG and Laevoroc Chemotherapy AG.
These changes are intended to ensure that the Board continues to meet Helix's evolving governance and capital markets requirements and has the composition and experience needed to support the company's clinical development and broader corporate objectives. The Board thanked Mr. Grabski for his service and contributions and wished him success in his future endeavors.
Helix BioPharma is a clinical-stage oncology company with a pipeline led by L-DOS47, an antibody-enzyme conjugate being developed as a combination therapy for non-small cell lung cancer (NSCLC). Additional pipeline candidates include LEUMUNA™, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors. The company's common shares are listed on the Toronto Stock Exchange (TSX: HBP), quoted on the OTC Pink Market (HBPCD), and listed on the Frankfurt Stock Exchange (FWB: HBP0).
The board changes come at a critical time as Helix advances its clinical programs and seeks to strengthen its governance structure to support its strategic objectives. The appointment of Dr. Mehrling, who has been leading the company's operations, aligns the board with the executive leadership and reinforces the company's commitment to its pipeline development. The strategic acquisition from Laevoroc, which included the pre-IND candidates LEUMUNA™ and GEMCEDA™, has been a key part of Helix's growth strategy, and this board adjustment reflects the company's focus on integrating those assets effectively.
Investors and stakeholders will be watching how these governance changes impact Helix's ability to execute on its clinical milestones and capital markets strategy. The company's ongoing work on L-DOS47 for NSCLC, a significant unmet medical need, remains a central focus. With the board now including the CEO, there is potential for more streamlined decision-making and a clearer alignment between management and governance, which could be crucial for advancing the pipeline and securing partnerships or funding.
Helix BioPharma continues to operate with a mandate to develop therapies for underserved patient populations, and these board adjustments are part of its effort to ensure it has the right leadership in place to navigate the complexities of clinical development and regulatory pathways. The company's shares are traded on multiple exchanges, reflecting its international presence and investor base. As it moves forward, the composition of the board will be a key factor in how it addresses the challenges and opportunities ahead.
For more information about Helix BioPharma and its pipeline, visit https://www.helixbiopharma.com/. Additional details on the strategic acquisition can be found at https://www.helixbiopharma.com/fy2025/helix-biopharma-secures-pre-ind-candidates-leumuna-and-gemceda-in-strategic-acquisition-from-the-laevoroc-group/.
